Vaccine, Molecular Immunology in the Era of Pandemic and Beyond
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Clinical Immunology".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3011
Special Issue Editors
Interests: immunotherapy; cardiovascular immunology; drug discovery; molecular biology; genetic engineering; human diseases
Special Issues, Collections and Topics in MDPI journals
2. UNMC, Omaha, NE, USA
Interests: gastrointestinal cancers; liver cancer; metabolic; therapeutic strategy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the age of the COVID-19 pandemic, the central focus of public health efforts has been shifted towards research into vaccines, immunobiology and molecular vaccines to control the pandemic as well as preserving other regular immunizations concurrently. Vaccine research and development has already saved many lives around the world, but still vaccine-preventable disease continue to cause significant deaths and economic burden globally as well.
Therefore, we are pleased to invite you to submit an article to this Special Issue of Vaccines, molecular immunology in the era of pandemic and beyond. The objective of this issue is to invite original research articles and reviews to enhance knowledge and better understanding of basic and immune responses after immunization of individuals in health and different ailments. Despite this, we also invite articles submitted on basic and clinical reviews, opinion and commentary pieces, visual pieces, and letters. The manuscripts outside these themes are also welcomed on the cellular, molecular, and behavioral response of vaccines, ethics, safety, and many other related areas.
We look forward to receiving your contributions.
Dr. Vinay Kumar
Dr. Surendra Shukla
Dr. Antresh Kumar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine production
- vaccine safety assessment
- vaccine safety
- immunobiology
- human diseases
